Heart Failure Drugs Market (2026-2032)

Heart Failure Drugs Market Trends & Overview

The Global Heart Failure Drugs Market was valued at approximately USD 18.4 billion in 2025 and is projected to reach approximately USD 28.0 billion by 2032, expanding at a CAGR of approximately 6.2% during 2026–2032.

Heart failure treatment is generating more pharmaceutical revenue per diagnosed patient as guideline-directed care increasingly combines several drug classes. ARNI, SGLT2 inhibitors, beta blockers, mineralocorticoid receptor antagonists, ACE inhibitors or ARBs, and diuretics are commonly used across the treatment pathway. The commercial effect is important because revenue growth comes not only from new diagnoses but also from a higher number of prescriptions per treated patient.

The addressable population is substantial, with approximately 64 million people estimated to be living with heart failure globally. The burden is concentrated in older populations, but rising obesity, hypertension, diabetes, and cardiovascular disease survival are also increasing treatment requirements among younger adults. In the United States, approximately 6.7–7.7 million adults are living with heart failure, while the lifetime risk is now estimated at roughly 1 in 4 adults. Heart failure contributed to 452,573 U.S. deaths in 2023, equivalent to approximately 14.6% of all deaths, showing why reducing hospitalization and mortality remains a major treatment priority.

How Are High-Value Drug Franchises Reshaping Heart Failure Pharmaceutical Spending?

The largest revenue shift is occurring through ARNI and SGLT2 inhibitors. Older therapies such as beta blockers, ACE inhibitors, ARBs, spironolactone, and loop diuretics continue to generate very high prescription volumes, but their widespread generic availability keeps revenue per prescription low. Newer branded therapies capture a much larger share of market value.

Novartis' Entresto remains the largest directly identifiable heart failure franchise. Worldwide Entresto sales reached approximately USD 7.75 billion in 2025. After allowing for hypertension use in countries such as Japan and China, approximately USD 6.9–7.1 billion of this revenue was attributable to heart failure.

SGLT2 inhibitors are gaining revenue more rapidly. AstraZeneca's Farxiga generated approximately USD 7.66 billion globally in 2024, up about 27.7% year over year, before increasing further in 2025. The product is used across diabetes, chronic kidney disease, and heart failure, so its total sales cannot be counted as heart failure revenue. Based on indication mix, approximately USD 2.5–2.6 billion of 2025 Farxiga sales are estimated to be linked to heart failure treatment. AstraZeneca's reported sales trend confirms that the franchise has become one of the company's largest cardiovascular, renal, and metabolic products.

Jardiance has followed a similar pattern. Boehringer Ingelheim reported approximately EUR 8.8 billion in Jardiance sales during 2025, while sales reached EUR 5.7 billion in the first half of 2026 alone. Boehringer explicitly identified expanding demand across heart failure, chronic kidney disease, and type 2 diabetes as the main reason for the franchise's growth. The first-half 2026 performance indicates that Jardiance remains one of the strongest-growing established cardiovascular and metabolic drug franchises globally.

The first-half 2026 number is particularly useful for market direction. Jardiance generated EUR 4.3 billion in H1 2025 and EUR 5.7 billion in H1 2026, showing a strong year-on-year increase. This growth is occurring even as several mature cardiovascular drugs face price competition, making SGLT2 inhibitors one of the clearest sources of incremental revenue in heart failure treatment.

Why Does HFrEF Still Generate the Largest Drug Revenue?

Heart failure with reduced ejection fraction is estimated to account for approximately 61% of global Heart Failure Drugs Market revenue in 2025, equivalent to around USD 11.2 billion. HFrEF generates the highest pharmaceutical spending because patients are commonly treated with several drug classes at the same time, increasing drug revenue per patient.

HFpEF is estimated to account for approximately 27% of market revenue, or about USD 5.0 billion, and is expected to grow faster through 2032. SGLT2 inhibitors have widened the commercially treated HFpEF population, while historically this group had fewer therapies that directly influenced major cardiovascular outcomes.

The shift is especially relevant in aging markets such as Japan. Japanese hospital cohorts commonly show HFpEF representing approximately 44%–62% of hospitalized heart failure cases, compared with roughly 21%–38% for HFrEF. A high HFpEF burden gives SGLT2 manufacturers a larger long-term treatment opportunity than would be suggested by HFrEF prevalence alone.

USA: High Treatment Intensity and Branded Therapy Use Sustain the Largest Revenue Pool

North America accounted for an estimated 37% of the global Heart Failure Drugs Market in 2025, equivalent to approximately USD 6.8 billion, with the United States contributing the majority of regional revenue.

The commercial base is supported by approximately 6.7–7.7 million U.S. adults living with heart failure. Heart failure contributed to around 452,573 deaths in 2023, while age-adjusted heart failure mortality increased by roughly 37% between 2010 and 2023. Hospitalization rates have also increased among adults younger than 65, broadening the treated population beyond traditional elderly patient groups.

Revenue growth is increasingly linked to greater use of higher-value therapies within guideline-directed care. ARNI and SGLT2 inhibitors are being used alongside established beta blockers, MRAs, ACE inhibitors or ARBs, and diuretics, increasing the number of prescriptions used per treated patient. This treatment intensity gives the U.S. market a higher pharmaceutical value per diagnosed patient than markets dominated by older generic therapies.

At the same time, generic sacubitril/valsartan is beginning to pressure branded Entresto revenue. The U.S. market is therefore shifting from pure branded-drug expansion toward a mix of higher treatment penetration and lower revenue per prescription in mature drug classes.

Germany: Large Diagnosed Population and Low New-Therapy Penetration Create Upgrade Potential

Germany's Heart Failure Drugs Market is estimated at approximately USD 1.25 billion in 2025 and is projected to reach around USD 1.81 billion by 2032, expanding at an estimated 5.4% CAGR during 2026–2032.

A nationwide analysis covering approximately 74.3 million statutorily insured people identified around 2.2 million heart failure patients annually, with median annual incidence of approximately 364,446 newly diagnosed patients. Prevalence rises sharply with age and reaches around 27.6% among people older than 90 years, creating a large recurring treatment base.

Prescription patterns show a clear difference between established and newer therapies. Among newly diagnosed patients, approximately 59.3% received ACE inhibitors or ARBs, 55.9% beta blockers, and 44.3% diuretics, while ARNI and SGLT2 penetration was only around 4.1% and 3.3%, respectively, during the historical observation period. This creates room for revenue growth as treatment shifts toward newer guideline-directed therapies within an already large patient population.

Germany also recorded approximately 37,633 heart failure deaths in 2024, showing that treatment need remains high despite broad access to cardiovascular medicines. However, the market remains heavily exposed to generic competition, reference pricing, and reimbursement controls. Growth is therefore more likely to come from therapy mix improvement than from drug-price increases.

Japan: High HFpEF Burden and Strong Uptake of Modern Therapies Support Market Expansion

Japan's Heart Failure Drugs Market is estimated at approximately USD 1.05 billion in 2025 and is projected to reach around USD 1.65 billion by 2032, expanding at an estimated 6.7% CAGR during 2026–2032.

The strongest commercial driver is Japan's high representation of heart failure with preserved ejection fraction. Japanese hospital studies report that HFpEF accounts for approximately 44%–62% of hospitalized heart failure cases. This creates a large treatment pool for SGLT2 inhibitors, which have widened therapeutic options in a patient group that historically had fewer disease-modifying treatments.

Prescription activity also shows strong adoption of newer cardiovascular brands. National claims-based estimates for fiscal 2024 placed Entresto prescription value at around JPY 83 billion, Farxiga at approximately JPY 100 billion, and Jardiance at roughly JPY 82 billion across their approved indications. Although these products are also used for hypertension, diabetes, and chronic kidney disease, their prescription scale demonstrates strong clinical penetration and a well-established base for continued heart failure use.

Cardiovascular diseases account for approximately 410,000 deaths annually in Japan, while heart failure burden remains concentrated among older patients. The key commercial opportunity therefore lies in expanding the share of diagnosed patients receiving modern guideline-directed therapies rather than relying on overall disease prevalence alone.

Japan's main revenue constraint is its regular national drug-price revision system. Prescription volumes can continue rising while reimbursement price reductions limit value growth, making treatment penetration more important than price expansion for the market through 2032.

How Are Generic Entry and Pricing Pressure Changing Market Growth?

The global market is likely to grow more slowly in revenue than in treatment volume. Entresto remains one of the world's largest cardiovascular franchises, but generic sacubitril/valsartan has already begun reducing branded revenue in the United States. Similar pressure will gradually appear in other markets as exclusivity expires.

The same dynamic will eventually affect SGLT2 inhibitors. Higher treatment penetration can increase the number of patients receiving dapagliflozin or empagliflozin, while generic competition lowers the value generated per prescription. The market can therefore show strong prescription growth without maintaining blockbuster-level branded revenue growth.

Germany is already highly exposed to this dynamic because low-cost generic cardiovascular medicines dominate treatment volume. Japan has greater near-term branded protection in several categories, but regular national reimbursement price revisions still reduce the revenue retained from increasing prescription demand.

Which Companies Hold the Largest Commercial Positions?

Novartis remains the largest heart-failure-focused pharmaceutical supplier by attributable revenue through Entresto. The franchise contributes an estimated USD 6.9–7.1 billion to the global heart failure market after adjustment for non-HF indications.

Boehringer Ingelheim and Eli Lilly form the next major competitive group through Jardiance. Boehringer's EUR 5.7 billion of Jardiance sales in H1 2026 reinforces the franchise's current momentum, but only part of that revenue belongs to heart failure because CKD and diabetes remain large indications.

AstraZeneca holds a similar position through Farxiga. Its USD 7.66 billion of 2024 global sales and continued growth into 2025 underline the scale of the franchise, although only about one-third of estimated sales are currently allocated to heart failure in the bottom-up market model.

Below these companies, Bayer and Merck participate through Verquvo, while generic companies increasingly compete for sacubitril/valsartan, ACE inhibitor, ARB, beta-blocker, MRA, and diuretic prescriptions.

What Will Support the Market Through 2032?

The Heart Failure Drugs Market is expected to move from dependence on a few blockbuster brands toward broader treatment penetration across several drug classes. SGLT2 inhibitors are likely to gain the most share because their addressable population extends across HFrEF, HFmrEF, and HFpEF. ARNI will remain a major treatment class, but revenue growth will increasingly be limited by generic competition.

Germany illustrates the volume-driven European model, with approximately 2.2 million treated heart failure patients and more than 37,600 annual deaths supporting continued prescription demand. Japan provides a different growth profile, where population aging, high HFpEF representation, and substantial Entresto, Farxiga, and Jardiance prescription values create a strong market for modern therapies. The central market shift is increasing share of patients receiving multiple higher-value therapies over longer treatment periods.